The Europe Metastatic Cancer Drugs Market would witness market growth of 6.7% CAGR during the forecast period (2023-2030).
Substantial drug discovery and development improvements have also facilitated the emergence of newer and more potent therapies for metastatic cancer. The treatment landscape has changed dramatically due to the introduction of targeted medicines, immunotherapies, and combination medications, improving patient outcomes. These cutting-edge therapies have increased the demand for metastatic cancer medications and helped the market for these medications expand.
Additionally, regulatory organizations like the European Medicines Agency (EMA) have established programs to speed up the approval process for medications for metastatic cancer. Promising pharmaceuticals can now reach the market more quickly because of fast-track designations, breakthrough therapy designations, and accelerated approvals. The favorable regulatory environment encourages the development of medications to treat metastatic cancer, which propels market expansion.
In the United Kingdom, approximately 48,000 individuals are diagnosed with lung cancer, and 35,000 die annually. According to 2015 data, the United Kingdom's Department of Health and Social Care invests significantly yearly in cancer-related treatment and services. With rise in the number of cancer cases especially the lung cancer patient, the Europe’s market is estimated to grow.
The Germany market dominated the Europe Metastatic Cancer Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,073.5 million by 2030. The UK market is exhibiting a CAGR of 5.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 7.5% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Indication, the market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma & Others. Based on Therapy, the market is segmented into Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Metastatic Cancer Drugs Market is Projected to reach USD 115.6 Billion by 2030, at a CAGR of 7.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Inc. and Sanofi S.A.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Providers
By Indication
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma & Others
By Therapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Chemotherapy
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Bristol Myers Squibb Company
- Merck & Co., Inc.
- AstraZeneca PLC
- Novartis AG
- Eli Lilly And Company
- Pfizer, Inc.
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Amgen, Inc.
- Sanofi S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Metastatic Cancer Drugs Market, by Distribution Channel
1.4.2 Europe Metastatic Cancer Drugs Market, by Indication
1.4.3 Europe Metastatic Cancer Drugs Market, by Therapy
1.4.4 Europe Metastatic Cancer Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Approvals & Trials
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. Europe Metastatic Cancer Drugs Market by Distribution Channel
5.1 Europe Hospital Pharmacies Market by Country
5.2 Europe Drug Store & Retail Pharmacies Market by Country
5.3 Europe Online Providers Market by Country
Chapter 6. Europe Metastatic Cancer Drugs Market by Indication
6.1 Europe Breast Cancer Market by Country
6.2 Europe Lung Cancer Market by Country
6.3 Europe Prostate Cancer Market by Country
6.4 Europe Colorectal Cancer Market by Country
6.5 Europe Melanoma & Others Market by Country
Chapter 7. Europe Metastatic Cancer Drugs Market by Therapy
7.1 Europe Targeted Therapy Market by Country
7.2 Europe Immunotherapy Market by Country
7.3 Europe Hormonal Therapy Market by Country
7.4 Europe Chemotherapy Market by Country
Chapter 8. Europe Metastatic Cancer Drugs Market by Country
8.1 Germany Metastatic Cancer Drugs Market
8.1.1 Germany Metastatic Cancer Drugs Market by Distribution Channel
8.1.2 Germany Metastatic Cancer Drugs Market by Indication
8.1.3 Germany Metastatic Cancer Drugs Market by Therapy
8.2 UK Metastatic Cancer Drugs Market
8.2.1 UK Metastatic Cancer Drugs Market by Distribution Channel
8.2.2 UK Metastatic Cancer Drugs Market by Indication
8.2.3 UK Metastatic Cancer Drugs Market by Therapy
8.3 France Metastatic Cancer Drugs Market
8.3.1 France Metastatic Cancer Drugs Market by Distribution Channel
8.3.2 France Metastatic Cancer Drugs Market by Indication
8.3.3 France Metastatic Cancer Drugs Market by Therapy
8.4 Russia Metastatic Cancer Drugs Market
8.4.1 Russia Metastatic Cancer Drugs Market by Distribution Channel
8.4.2 Russia Metastatic Cancer Drugs Market by Indication
8.4.3 Russia Metastatic Cancer Drugs Market by Therapy
8.5 Spain Metastatic Cancer Drugs Market
8.5.1 Spain Metastatic Cancer Drugs Market by Distribution Channel
8.5.2 Spain Metastatic Cancer Drugs Market by Indication
8.5.3 Spain Metastatic Cancer Drugs Market by Therapy
8.6 Italy Metastatic Cancer Drugs Market
8.6.1 Italy Metastatic Cancer Drugs Market by Distribution Channel
8.6.2 Italy Metastatic Cancer Drugs Market by Indication
8.6.3 Italy Metastatic Cancer Drugs Market by Therapy
8.7 Rest of Europe Metastatic Cancer Drugs Market
8.7.1 Rest of Europe Metastatic Cancer Drugs Market by Distribution Channel
8.7.2 Rest of Europe Metastatic Cancer Drugs Market by Indication
8.7.3 Rest of Europe Metastatic Cancer Drugs Market by Therapy
Chapter 9. Company Profiles
9.1 Bristol Myers Squibb Company
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Merck & Co., Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.6 SWOT Analysis
9.3 AstraZeneca PLC
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 SWOT Analysis
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.6 SWOT Analysis
9.5 Eli Lilly And Company
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.6 SWOT Analysis
9.6 Pfizer, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional & Segmental Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.6 SWOT Analysis
9.7 F. Hoffmann-La Roche Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials & Approvals:
9.7.6 SWOT Analysis
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.6 SWOT Analysis
9.9 Amgen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expenses
9.9.5 SWOT Analysis
9.10. Sanofi S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.6 SWOT Analysis
TABLE 1 Europe Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 2 Europe Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Metastatic Cancer Drugs Market
TABLE 4 Product Launches And Product Expansions– Metastatic Cancer Drugs Market
TABLE 5 Acquisition and Mergers– Metastatic Cancer Drugs Market
TABLE 6 Approvals & Trials– Metastatic Cancer Drugs Market
TABLE 7 Europe Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 Europe Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 Europe Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 Europe Drug Store & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 Europe Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 14 Europe Online Providers Market by Country, 2023 - 2030, USD Million
TABLE 15 Europe Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 16 Europe Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 17 Europe Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 18 Europe Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 19 Europe Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 21 Europe Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 22 Europe Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 23 Europe Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 25 Europe Melanoma & Others Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe Melanoma & Others Market by Country, 2023 - 2030, USD Million
TABLE 27 Europe Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 28 Europe Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 29 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 30 Europe Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 31 Europe Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 32 Europe Immunotherapy Market by Country, 2023 - 2030, USD Million
TABLE 33 Europe Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 34 Europe Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 35 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 36 Europe Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 37 Europe Metastatic Cancer Drugs Market by Country, 2019 - 2022, USD Million
TABLE 38 Europe Metastatic Cancer Drugs Market by Country, 2023 - 2030, USD Million
TABLE 39 Germany Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 40 Germany Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 41 Germany Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Germany Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 Germany Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 44 Germany Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 45 Germany Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 46 Germany Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 47 UK Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 48 UK Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 49 UK Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 UK Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 UK Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 52 UK Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 53 UK Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 54 UK Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 55 France Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 56 France Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 57 France Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 France Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 France Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 60 France Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 61 France Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 62 France Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 63 Russia Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 64 Russia Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 65 Russia Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Russia Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Russia Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 68 Russia Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 69 Russia Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 70 Russia Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 71 Spain Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 72 Spain Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 73 Spain Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Spain Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Spain Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 76 Spain Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 77 Spain Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 78 Spain Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 79 Italy Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 80 Italy Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 81 Italy Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Italy Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Italy Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 84 Italy Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 85 Italy Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 86 Italy Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 87 Rest of Europe Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 88 Rest of Europe Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 89 Rest of Europe Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 90 Rest of Europe Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 91 Rest of Europe Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 92 Rest of Europe Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 93 Rest of Europe Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 94 Rest of Europe Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 95 Key Information – Bristol Myers Squibb Company
TABLE 96 KEY INFORMATION - Merck & Co., Inc.
TABLE 97 KEY INFORMATION – AstraZeneca PLC
TABLE 98 Key Information – Novartis AG
TABLE 99 Key Information – Eli Lilly And Company
TABLE 100 Key Information – Pfizer, Inc.
TABLE 101 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 102 Key Information – Johnson & Johnson
TABLE 103 Key Information – Amgen, Inc.
TABLE 104 Key Information – Sanofi S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Metastatic Cancer Drugs Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Metastatic Cancer Drugs Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
FIG 7 Porter’s Five Forces Analysis - Metastatic Cancer Drugs Market
FIG 8 Europe Metastatic Cancer Drugs Market share by Distribution Channel, 2022
FIG 9 Europe Metastatic Cancer Drugs Market share by Distribution Channel, 2030
FIG 10 Europe Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 Europe Metastatic Cancer Drugs Market share by Indication, 2022
FIG 12 Europe Metastatic Cancer Drugs Market share by Indication, 2030
FIG 13 Europe Metastatic Cancer Drugs Market by Indication, 2019 - 2030, USD Million
FIG 14 Europe Metastatic Cancer Drugs Market share by Therapy, 2019
FIG 15 Europe Metastatic Cancer Drugs Market share by Therapy, 2030
FIG 16 Europe Metastatic Cancer Drugs Market by Therapy, 2019 - 2030, USD Million
FIG 17 Europe Metastatic Cancer Drugs Market share by Country, 2022
FIG 18 Europe Metastatic Cancer Drugs Market share by Country, 2030
FIG 19 Europe Metastatic Cancer Drugs Market by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Bristol Myers Squibb Company
FIG 21 Swot Analysis: Merck & Co., Inc.
FIG 22 Swot Analysis: AstraZeneca PLC
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Eli Lilly And Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Swot Analysis: Pfizer, Inc.
FIG 27 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 28 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 29 Swot Analysis: Johnson & Johnson
FIG 30 Swot Analysis: Amgen, Inc.
FIG 31 Swot Analysis: Sanofi S.A.